Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Dow
Colorcon
Harvard Business School
Merck

Last Updated: January 26, 2023

CLINICAL TRIALS PROFILE FOR CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Clindamycin Phosphate In 0.9% Sodium Chloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00160394 ↗ Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris Completed GlaxoSmithKline Phase 4 2004-12-01 Comparing the efficacy and safety of a gel formulation containing a combination of clindamycin phosphate (equivalent to 1% clindamycin) and benzoyl peroxide (5%) once daily with a gel containing 0.1% adapalene once daily in the treatment of acne vulgaris of mild to moderate severity.
NCT00160394 ↗ Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris Completed Stiefel, a GSK Company Phase 4 2004-12-01 Comparing the efficacy and safety of a gel formulation containing a combination of clindamycin phosphate (equivalent to 1% clindamycin) and benzoyl peroxide (5%) once daily with a gel containing 0.1% adapalene once daily in the treatment of acne vulgaris of mild to moderate severity.
NCT00219570 ↗ Dalacin-T Gel Post Approval Study Completed Acronet Phase 4 2005-01-01 To investigate, in a comparison vs. Acuatim cream (nadifloxacin cream), the efficacy and safety of Dalacin T Gel (clindamycin phosphate gel) as a therapeutic medication for acne vulgaris in acne vulgaris patients, including children ages 13 and up, in order to clarify the clinical positioning of Dalacin T Gel.
NCT00219570 ↗ Dalacin-T Gel Post Approval Study Completed Bellsystem24 , Inc. Phase 4 2005-01-01 To investigate, in a comparison vs. Acuatim cream (nadifloxacin cream), the efficacy and safety of Dalacin T Gel (clindamycin phosphate gel) as a therapeutic medication for acne vulgaris in acne vulgaris patients, including children ages 13 and up, in order to clarify the clinical positioning of Dalacin T Gel.
NCT00219570 ↗ Dalacin-T Gel Post Approval Study Completed Mitsubishi Kagaku Bio-Clinical Laboratories, inc Phase 4 2005-01-01 To investigate, in a comparison vs. Acuatim cream (nadifloxacin cream), the efficacy and safety of Dalacin T Gel (clindamycin phosphate gel) as a therapeutic medication for acne vulgaris in acne vulgaris patients, including children ages 13 and up, in order to clarify the clinical positioning of Dalacin T Gel.
NCT00219570 ↗ Dalacin-T Gel Post Approval Study Completed Parexel Phase 4 2005-01-01 To investigate, in a comparison vs. Acuatim cream (nadifloxacin cream), the efficacy and safety of Dalacin T Gel (clindamycin phosphate gel) as a therapeutic medication for acne vulgaris in acne vulgaris patients, including children ages 13 and up, in order to clarify the clinical positioning of Dalacin T Gel.
NCT00219570 ↗ Dalacin-T Gel Post Approval Study Completed SACT INTERNATIONAL Co., LTD. Phase 4 2005-01-01 To investigate, in a comparison vs. Acuatim cream (nadifloxacin cream), the efficacy and safety of Dalacin T Gel (clindamycin phosphate gel) as a therapeutic medication for acne vulgaris in acne vulgaris patients, including children ages 13 and up, in order to clarify the clinical positioning of Dalacin T Gel.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Clindamycin Phosphate In 0.9% Sodium Chloride

Condition Name

Condition Name for Clindamycin Phosphate In 0.9% Sodium Chloride
Intervention Trials
Acne Vulgaris 18
Bacterial Vaginosis 3
Acne 2
Vaginal Discharge: Color, Odor, and Consistency; 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Clindamycin Phosphate In 0.9% Sodium Chloride
Intervention Trials
Acne Vulgaris 20
Vaginosis, Bacterial 3
Vaginal Diseases 2
Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Clindamycin Phosphate In 0.9% Sodium Chloride

Trials by Country

Trials by Country for Clindamycin Phosphate In 0.9% Sodium Chloride
Location Trials
United States 90
India 19
China 10
Russian Federation 4
Puerto Rico 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Clindamycin Phosphate In 0.9% Sodium Chloride
Location Trials
New York 6
Pennsylvania 6
California 5
Texas 5
Florida 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Clindamycin Phosphate In 0.9% Sodium Chloride

Clinical Trial Phase

Clinical Trial Phase for Clindamycin Phosphate In 0.9% Sodium Chloride
Clinical Trial Phase Trials
Phase 4 10
Phase 3 9
Phase 2/Phase 3 1
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Clindamycin Phosphate In 0.9% Sodium Chloride
Clinical Trial Phase Trials
Completed 25
Unknown status 4
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Clindamycin Phosphate In 0.9% Sodium Chloride

Sponsor Name

Sponsor Name for Clindamycin Phosphate In 0.9% Sodium Chloride
Sponsor Trials
GlaxoSmithKline 6
Stiefel, a GSK Company 4
Medicis Pharmaceutical Corporation 2
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Clindamycin Phosphate In 0.9% Sodium Chloride
Sponsor Trials
Industry 35
Other 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
McKesson
Dow
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.